Katherine Stultz
Direktor/Vorstandsmitglied bei KRONOS BIO, INC.
Vermögen: - $ am 31.05.2024
Aktive Positionen von Katherine Stultz
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
KRONOS BIO, INC. | Direktor/Vorstandsmitglied | 10.04.2023 | - |
Independent Dir/Board Member | 10.04.2023 | - | |
Ocelot Bio, Inc.
Ocelot Bio, Inc. Pharmaceuticals: MajorHealth Technology Ocelot Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on improving outcomes for patients with end-stage liver disease (ESLD), particularly those suffering from hepatorenal syndrome with acute kidney injury (HRS-AKI) and refractory ascites. The company is based in San Diego, CA. The company is developing therapeutic peptides to treat complications of decompensated cirrhosis, a condition in which the liver is scarred and permanently damaged, leading to liver failure. HRS-AKI is a life-threatening consequence of portal hypertension, which causes a significant drop in arterial pressure and renal perfusion. Ocelot Bio is in early-stage development of OCE-205 for the treatment of ascites, a complication of ESLD-induced portal hypertension that leads to the accumulation of fluid in the peritoneal cavity. The company was founded by Geoffrey Harris, and Katherine Vega Stultz has been the CEO of the company since 2022. | Vorstandsvorsitzender | 23.03.2022 | - |
Präsident | 23.03.2022 | - |
Karriereverlauf von Katherine Stultz
Ehemalige bekannte Positionen von Katherine Stultz
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
LENZ THERAPEUTICS, INC. | Geschäftsführer | 01.08.2020 | 31.12.2021 |
CELGENE | Corporate Officer/Principal | 01.08.2005 | 01.01.2020 |
Ausbildung von Katherine Stultz
Cornell University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 6 |
Operativ
Chief Operating Officer | 1 |
Undergraduate Degree | 1 |
Corporate Officer/Principal | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
KRONOS BIO, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Graphite Bio, Inc.
Graphite Bio, Inc. BiotechnologyHealth Technology Graphite Bio, Inc. is a clinical-stage gene editing company. It engages in the business of developing therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA. | Health Technology |
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Ocelot Bio, Inc.
Ocelot Bio, Inc. Pharmaceuticals: MajorHealth Technology Ocelot Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on improving outcomes for patients with end-stage liver disease (ESLD), particularly those suffering from hepatorenal syndrome with acute kidney injury (HRS-AKI) and refractory ascites. The company is based in San Diego, CA. The company is developing therapeutic peptides to treat complications of decompensated cirrhosis, a condition in which the liver is scarred and permanently damaged, leading to liver failure. HRS-AKI is a life-threatening consequence of portal hypertension, which causes a significant drop in arterial pressure and renal perfusion. Ocelot Bio is in early-stage development of OCE-205 for the treatment of ascites, a complication of ESLD-induced portal hypertension that leads to the accumulation of fluid in the peritoneal cavity. The company was founded by Geoffrey Harris, and Katherine Vega Stultz has been the CEO of the company since 2022. | Health Technology |
- Börse
- Insiders
- Katherine Stultz
- Erfahrung